Grape-Derived Exosome-like Nanoparticles Ameliorate Prediabetes in Mice via Amino Acid Metabolic Reprogramming.

Authors

Zaoling Liu, Shuya Cai, Aerna Qiayimaerdan, Yile Tang, Jin Su, Zisen Yang

Published in

International journal of molecular sciences. Volume 27. Issue 15. Aug 02, 2026. Epub Aug 02, 2026.

Abstract

This study investigates the effects of grape-derived exosomes on prediabetic mice and elucidates their underlying mechanisms through an integrated metabolomics approach. A prediabetic mouse model was established, with 18 mice randomly assigned to three groups: model control group, grape exosome treatment group, and antioxidant nutrient supplementation group. Therapeutic efficacy was assessed using fasting plasma glucose (FPG) and homeostasis model assessment of β-cell function (HOMA-β). Intestinal content metabolites were profiled via both untargeted ultra-high performance liquid chromatography coupled with orbitrap electrospray mass spectrometry (UHPLC-OE-MS) and targeted metabolomics analyses. Grape exosomes effectively mitigated prediabetes progression. Untargeted metabolomics revealed 1222 downregulated and 425 upregulated metabolites in the grape exosome group relative to the model control group, among which riboflavin (upregulated) was potentially associated with amino acid metabolism. Targeted metabolomics identified 23 upregulated and 41 downregulated metabolites, with glycine showing a significant elevation. Notably, both the grape exosome group and antioxidant nutrient supplementation group exhibited increased glycine levels and shared enriched metabolic pathways, including D-glutamine and D-glutamate metabolism, phenylalanine, tyrosine and tryptophan biosynthesis, as well as valine, leucine, and isoleucine biosynthesis. Integrated untargeted and targeted metabolomics analysis demonstrates that grape exosomes ameliorate diabetes-related metabolic disorders and slow the progression of prediabetes, indicating that grape-derived exosomes have great potential as a functional intervention agent for early glucose metabolism dysfunction.

PMID:
42589601
Bibliographic data and abstract were imported from PubMed on 13 Aug 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.